Literature DB >> 24284475

Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample.

Adam R Winstock1, Stephen Kaar, Rohan Borschmann.   

Abstract

This paper presents original research on prevalence, user characteristics and effect profile of N,N-dimethyltryptamine (DMT), a potent hallucinogenic which acts primarily through the serotonergic system. Data were obtained from the Global Drug Survey (an anonymous online survey of people, many of whom have used drugs) conducted between November and December 2012 with 22,289 responses. Lifetime prevalence of DMT use was 8.9% (n=1980) and past year prevalence use was 5.0% (n=1123). We explored the effect profile of DMT in 472 participants who identified DMT as the last new drug they had tried for the first time and compared it with ratings provided by other respondents on psilocybin (magic mushrooms), LSD and ketamine. DMT was most often smoked and offered a strong, intense, short-lived psychedelic high with relatively few negative effects or "come down". It had a larger proportion of new users compared with the other substances (24%), suggesting its popularity may increase. Overall, DMT seems to have a very desirable effect profile indicating a high abuse liability that maybe offset by a low urge to use more.

Entities:  

Keywords:  DMT; Dimethyltryptamine; Indolealkylamine; LSD; Novel psychoactive substance; ketamine; legal highs; magic mushrooms

Mesh:

Substances:

Year:  2013        PMID: 24284475     DOI: 10.1177/0269881113513852

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  21 in total

1.  Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Neuropharmacology       Date:  2015-02       Impact factor: 5.250

2.  Trends in DMT and other tryptamine use among young adults in the United States.

Authors:  Joseph J Palamar; Austin Le
Journal:  Am J Addict       Date:  2018-10

3.  Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Pharmacol Rep       Date:  2016-02-05       Impact factor: 3.024

Review 4.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

5.  Assessing self-reported use of new psychoactive substances: The impact of gate questions.

Authors:  Joseph J Palamar; Patricia Acosta; Fermín Fernández Calderón; Scott Sherman; Charles M Cleland
Journal:  Am J Drug Alcohol Abuse       Date:  2017-05-09       Impact factor: 3.829

6.  Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting.

Authors:  Joseph J Palamar; Silvia S Martins; Mark K Su; Danielle C Ompad
Journal:  Drug Alcohol Depend       Date:  2015-09-03       Impact factor: 4.492

7.  Phenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience.

Authors:  David Wyndham Lawrence; Robin Carhart-Harris; Roland Griffiths; Christopher Timmermann
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

8.  Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects.

Authors:  Rafael L Lancelotta; Alan K Davis
Journal:  J Psychoactive Drugs       Date:  2020-03-09

9.  A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines.

Authors:  Joseph J Palamar; Patricia Acosta
Journal:  Hum Psychopharmacol       Date:  2020-01-07       Impact factor: 1.672

10.  Shifting characteristics of ecstasy users ages 12-34 in the United States, 2007-2014.

Authors:  Joseph J Palamar; Pia M Mauro; Benjamin H Han; Silvia S Martins
Journal:  Drug Alcohol Depend       Date:  2017-10-06       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.